We use cookies to ensure that we give you the best experience of our website. If you accept without changing your settings, we assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
text.skipToContent text.skipToNavigation

{{ addToCartData.mixPtRmWarning }}

Do you want to proceed?

{{requestQuote.productName}}; {{requestQuote.form.productCode}}

Thank you

We will respond to your enquiry shortly.

Something went wrong, please try again later.

Bulk Order
If not, click 'cancel'. You can also save this item for later.
If not, click 'cancel'. You can also save this item for later.

Movember: The Mo is calling!



To mark this year’s Movember campaign: ‘The Mo is calling’, we’re celebrating advances in the design and manufacture of prostate cancer drugs - and explaining how LGC Standards can help you to get ‘mo’ from your research.


‘Men’s health is in crisis. Men are dying on average 4.5 years earlier than women, and for largely preventable reasons’, is the stark call to action from leading men’s health charity Movember – set up to address diverse health causes, from prostate and testicular cancer to mental health. Here at LGC Standards, we’re marking Movember 2023 by celebrating the hard work of scientists working to design and manufacture prostate cancer drugs - and by explaining how LGC can support you.


Prostate cancer is the second most diagnosed cancer in men. Over the past decade, breakthroughs in genomics and molecular imaging techniques have underpinned significant advancements in our understanding of the complex, heterogeneous nature of prostate cancer biology – thereby laying the foundations for the design of targeted therapies such as the PARP inhibitor niraparib, and the radio-pharmaceutical lutetium.


LGC standards’ TRC brand contains a vast range of research chemicals, including many novel molecules, which are used widely within prostate cancer research and development. Our products help scientists to probe tumour biology and drug targets ranging from DNA repair enzymes to growth factor receptors such as VEGF and PDGF, as well as biomarkers including PSMA. TRC’s utility in prostate cancer is emphasised by an extensive range of citations in research areas such as novel drug targets, biomarker discovery and the development of nanotech drug formulations.


New pharmacological modalities such as PROTACs and radio-pharmaceuticals have created exciting possibilities for addressing old clinical challenges in new ways – giving us the potential to circumvent previously intractable problems such as drug resistance, and push back the boundaries of what is considered an ‘undruggable target’. However, increasing complexity in prostate cancer drug design has created a parallel need for advancements in reference standards to support the discovery and manufacture of these medications - and LGC Standards is proud to have delivered many catalogue and bespoke solutions that support our customers in this work. Our Mikromol brand provides ISO 17025-accredited API, impurity, and excipient reference materials that are used to support the manufacture of prostate cancer hormone therapies such as cyproterone acetate and enzalutamide, as well as commonly used chemotherapies including docetaxel and cabazitaxel.


Despite significant developments in targeted therapies, five-year survival rates for some forms of prostate cancer remain poor, for example, at just 30% for patients with distal metastases. This highlights the urgent need to develop more effective medications and treatment combinations. Therefore LGC would like to say a big ‘Thank You’ to everyone taking part in the Movember initiative, which has raised an astounding £873.9 million to date in support of men’s health causes, with Prostate Cancer UK the main beneficiary.



LGC Standards – for all your research chemical and drug discovery needs


LGC standards’ TRC brand has more than 40 years’ experience working through some of the most complex synthetic pathways to deliver you high quality research chemicals. We have a large portfolio of APIs, bioactive molecules, drug derivatives, impurities and SILS, as well as synthetic chemistry tools such as building blocks and linkers. Our TRC range includes many unique molecules for research into prostate cancer. And, if you can’t find the chemical you need, our skilled team of synthetic chemists would relish the challenge of designing it for you! Email info.trc@lgcgroup.com for more details. 


We also distribute an unparalleled collection of in vitro tools for cancer research in Europe and Africa from the world’s largest biorepository, ATCC. Our range includes the world’s largest collection of cancer cell lines as well as organoids, and immuno-oncology reporters.


To support your analysis and help ensure the accuracy of your quality control processes, LGC Mikromol supplies a full range of API, impurity and excipient reference standards, produced to the highest possible quality standards, under ISO 17025 and ISO 17034 accreditations.


Punchout session timeout warning

Your punchout session will expire in1 min59 sec.

Select "Continue session" to extend your session.